Endocyte (ECYT) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Endocyte (ECYT) Misses Q1 EPS by 2c

Endocyte Reports First Quarter 2015 Financial Results and Provides Update on Clinical Progress

May 7, 2015 4:02 PM EDT

- Dose Escalation for EC1456 and EC1169 Move to Fifth Dosing Cohorts Evaluating Two Schedules for Each Agent -

- Conference Call Today at 4:30 p.m. EDT -

WEST LAFAYETTE, Ind., May 7, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2015, and provided a clinical update.

"We have successfully moved both EC1456, a folate-targeted tubulysin, and EC1169, a... More